https://www.prnewswire.com/news-releases/fanapt-shown-to-be-effective-in-bipolar-i-disorder-in-phase-iii-clinical-study-301705863.html
0
0
Fanapt® Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study - PR Newswire
12/19/22 at 12:00pm
Organization
PRNewswire
Authors
Details
36 words
Summarize
Health Drugs & Medications Fanapt Bipolar I Disorder Phase III Clinical Study PRNewswire Vanda Pharmaceuticals Inc Nasdaq Phase III Vanda
/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today reported positive results in a Phase III clinical study of Fanapt® (iloperidone...
Create an account or login to join the discussion